Stocks · News reference

PolyPid shares are trading lower. The company announced it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100.

Jul 21, 2026, 2:30 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 12, 2026, 11:30 AMBenzinga Newsdesk
PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 55.13 percent increase over losses of $(0.78) per share from the same
PYPD
BenzingaJul 29, 2026, 12:50 PMBenzinga Newsdesk
PolyPid shares are trading higher after the company announced that the FDA accepted its New Drug Application and granted it a Priority Review for D-PLEX100
PYPD
BenzingaJul 29, 2026, 12:34 PMBenzinga Newsdesk
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28
PYPD
BenzingaJul 21, 2026, 3:58 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.
PYPD